{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:10:37Z","timestamp":1788844237495,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>The widespread adoption of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and related anti-obesity medications has transformed obesity treatment. However, limited data are available regarding the characteristics of patients receiving prescriptions for these medications and patients\u2019 real-world experiences with medication access, utilization, and supportive care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The CAMP (Characteristics of Anti-Obesity Medication Patients) study was conducted in a large academic health system. Phase I characterized demographic, clinical, and social determinants of health among adults prescribed semaglutide or tirzepatide for weight management between July 2023 and June 2024. Phase II was an online survey assessing prescription fulfillment, medication use, payment methods, discontinuation, counseling, and referrals to additional services. Descriptive statistics and bivariate analyses were used to summarize findings and examine differences between patients receiving a prescription for the lowest dose versus the higher doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 21,610 adults prescribed semaglutide or tirzepatide were identified through electronic health records in Phase I, and 2,628 completed the Phase II patient survey. Patients in Phase I were predominantly female, White, and privately insured, with a mean age of 49\u202fyears and mean BMI of 36\u202fkg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Most prescriptions were written by primary care providers. Among survey respondents in Phase II, 90.1% reported successfully filling their initial prescription and 80.5% remained on treatment. Among the 512 respondents who reported discontinued treatment, the most common reasons were insurance coverage discontinuation (37.7%), high medication costs (20.3%), and side effects (27.1%). Although 88.0% of respondents reported receiving medication-related instructions, only 27.0% reported receiving a referral to an additional health service, most commonly nutrition counseling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Patients prescribed contemporary anti-obesity medications were predominantly female, White, and privately insured. Financial barriers were the main reasons for treatment discontinuation, and potentially important referrals to nutrition and behavioral services were infrequent. These findings provide important real-world insights into the implementation of anti-obesity pharmacotherapy and identify leverage points for improving access, continued use, and multidisciplinary obesity treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2026.1931188","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:48Z","timestamp":1788841608000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient characteristics and early experiences with anti-obesity medications: the CAMP study"],"prefix":"10.3389","volume":"13","author":[{"given":"Colleen","family":"Tewksbury","sequence":"first","affiliation":[{"name":"Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma Adelia","family":"Soliva","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Scheffey","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pui Lui","family":"Kwong","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Glanz","sequence":"additional","affiliation":[{"name":"Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania","place":["Philadelphia, PA, United States"]},{"name":"Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania","place":["Philadelphia, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.15620\/cdc\/159281","volume-title":"Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023","author":"Emmerich","year":"2024"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the world obesity federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes Rev"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1001\/jama.2024.27676","article-title":"Trends in obesity-related measures among US children, adolescents, and adults","volume":"333","author":"Emmerich","year":"2025","journal-title":"JAMA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an Endocrine Society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metabol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Can Med Assoc J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41366-024-01525-3","article-title":"The past, present, and future of behavioral obesity treatment","volume":"49","author":"Chao","year":"2025","journal-title":"Int J Obes"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","article-title":"Tirzepatide for the treatment of obstructive sleep apnea and obesity","volume":"391","author":"Malhotra","year":"2024","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/ANNALS-24-02870","article-title":"Trends in utilization of glucose-and weight-lowering medications after tirzepatide approval in the United States: a population-based cohort study","volume":"178","author":"Ostrominski","year":"2025","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/oby.24186","article-title":"Contemporary treatment patterns of overweight and obesity: insights from the mass general Brigham health care system","volume":"33","author":"Ostrominski","year":"2025","journal-title":"Obesity"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"100237","DOI":"10.1016\/j.obpill.2025.100237","article-title":"Taking back control: the experience of adults using semaglutide and tirzepatide for obesity treatment-a qualitative study","volume":"17","author":"Trocchio","year":"2025","journal-title":"Obes Pillars"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-05468","article-title":"Leveraging real-world evidence to inform regulatory, clinical, and coverage decisions related to glucagon-like peptide-1\u2013based therapies: synopsis of a National Institute of Diabetes and Digestive and Kidney Diseases workshop","author":"Arterburn","year":"2026","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.gtc.2023.02.003","article-title":"Disparities in access and quality of obesity care","volume":"52","author":"Washington","year":"2023","journal-title":"Gastroenterol Clin"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.japhpi.2025.100081","article-title":"Clinical impact of GLP-1 and GIP\/GLP-1 agonist access barriers in primary care","volume":"3","author":"Cochran","year":"2025","journal-title":"JAPhA Pract Innov"},{"key":"ref18","author":"Dixon","year":"2025"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e0284474","DOI":"10.1371\/journal.pone.0284474","article-title":"Primary care providers\u2019 perceived barriers to obesity treatment and opportunities for improvement: a mixed methods study","volume":"18","author":"Oshman","year":"2023","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring, Md)"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jand.2024.10.023","article-title":"Incretin-based therapies and lifestyle interventions: the evolving role of registered dietitian nutritionists in obesity care","volume":"125","author":"Gigliotti","year":"2025","journal-title":"J Acad Nutr Diet"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1001\/jama.2026.4106","article-title":"Lifestyle modification and incretin-based therapy for obesity","volume":"335","author":"Kushner","year":"2026","journal-title":"JAMA"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the obesity medicine association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1931188\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T04:26:49Z","timestamp":1788841609000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2026.1931188\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":23,"alternative-id":["10.3389\/fnut.2026.1931188"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2026.1931188","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1931188"}}